title: Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients.
abstract: The increase in morbidity and mortality due to end-stage liver disease has fueled recent guidelines that recommend consideration of treatment for hepatitis C in human immunodeficiency virus (HIV)-infected patients. Unfortunately, studies indicate that few patients coinfected with HIV and hepatitis C virus (HCV) are treated for their underlying hepatitis because of ongoing substance abuse, depression, chaotic lifestyles, homelessness, and perceived nonadherence. The structured environment of the prison system enables clinicians to provide complicated therapies for HCV to HIV-infected patients in combination with substance abuse programs. Furthermore, adherence to and adverse effects of therapy can be closely monitored. Offering treatment for HCV infection during incarceration to HIV-seropositive persons is highly efficient and targets underserved minority patients who have limited access to care in the community.
authors.affiliation: Division of Infectious Diseases, Lemuel Shattuck Hospital, Jamaica Plain, MA 02130, USA. bmcgovern@tufts-nemc.org
authors.forename: Barbara
authors.initials: B
authors.lastname: McGovern
authors.forename: Joseph
authors.initials: J
authors.lastname: Fiore
authors.forename: Alysse
authors.initials: A
authors.lastname: Wurcel
authors.forename: Paul
authors.initials: P
authors.lastname: Taglienti
authors.forename: Meg
authors.initials: M
authors.lastname: Bradley
authors.forename: Susan
authors.initials: S
authors.lastname: Galvin
authors.forename: George
authors.initials: G
authors.lastname: Libone
authors.forename: Jean
authors.initials: J
authors.lastname: Ramsey
authors.forename: Valerie
authors.initials: V
authors.lastname: Molinaro-Gudas
authors.forename: Stephen
authors.initials: S
authors.lastname: Drewniak
authors.forename: Carol
authors.initials: C
authors.lastname: Amick
authors.forename: Anjali
authors.initials: A
authors.lastname: Andalkar
authors.forename: Harriet
authors.initials: H
authors.lastname: Scheft
authors.forename: Ioana
authors.initials: I
authors.lastname: Bica
mesh_terms: D003710:Demography; D004347:Drug Interactions; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008099:Liver / Q000473:pathology; D008297:Male; D011329:Prisoners; D012254:Ribavirin / Q000008:administration & dosage; D019966:Substance-Related Disorders / Q000150:complications / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D016898:Interferon-alpha; D012254:Ribavirin